AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Sight Sciences, Inc.
Video analysis: SGHT
All videosNo video analysis for this stock yet. Request one from our team.
News: SGHT
BlackRock Inc. Purchases New Shares in Sight Sciences, Inc. $SGHT
BlackRock Inc. acquired a new stake in Sight Sciences, Inc. (NASDAQ: SGHT) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,083,108 shares of the company's stock, valued at approximately $16,710,000. BlackRock Inc. owned approximately 5.67% of Sight Sciences
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
Sight Sciences Q2 Earnings Call Highlights
Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.
Sight Sciences Q2 Earnings Call Highlights
Sight Sciences (NASDAQ: SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance. Total revenue for the quarter ended June 30 was $23.4
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
